{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T14:01:05Z","timestamp":1785765665789,"version":"3.56.0"},"reference-count":30,"publisher":"American Chemical Society (ACS)","issue":"8","license":[{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"funder":[{"DOI":"10.13039\/501100004829","name":"Science and Technology Department of Sichuan Province","doi-asserted-by":"publisher","award":["2025ZDZX0046"],"award-info":[{"award-number":["2025ZDZX0046"]}],"id":[{"id":"10.13039\/501100004829","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018554","name":"Science and Technology Program of Gansu Province","doi-asserted-by":"publisher","award":["23ZDFA014"],"award-info":[{"award-number":["23ZDFA014"]}],"id":[{"id":"10.13039\/501100018554","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/na","name":"medical isotope production technology and targeted radiopharmaceuticals research of Gansu Isotope Laboratory","doi-asserted-by":"publisher","award":["GSTWS2501"],"award-info":[{"award-number":["GSTWS2501"]}],"id":[{"id":"10.13039\/na","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Building upon our previous work on [68Ga]Ga\/[177Lu]Lu-DOTA-Ibandronate and its demonstrated clinical applicability, this study investigates the biological behavior and translational potential of the novel therapeutic radiopharmaceutical terbium-161 (161Tb)-labeled DOTA-IBA. The radiolabeling parameters of [161Tb]Tb-DOTA-IBA were first optimized, followed by a systematic assessment of its physicochemical characteristics. Biodistribution, micro-SPECT\/CT imaging, and therapeutic efficacy were evaluated in a 4T1 mouse model of bone metastasis to determine pharmacokinetics and bone-targeting capacity. Safety was verified through dose-escalation experiments. Furthermore, a preliminary clinical evaluation was performed in one volunteer with bone metastases to validate safety and initial therapeutic efficacy. [161Tb]Tb-DOTA-IBA was obtained with radiochemical purity exceeding 98%, demonstrating excellent bone-targeting selectivity and retention, with a 24 h bone uptake of 30.61 \u00b1 4.61% ID\/g, which is substantially higher than in soft tissues. In a patient receiving 370 MBq, marked pain relief was achieved, reflected by decreased VAS scores, with therapeutic benefit lasting 8\u201312 weeks and no observed toxic reactions. The compound exhibited favorable pharmacokinetics and safety, with no \u2265 grade 3 adverse events. Overall, [161Tb]Tb-DOTA-IBA displayed high tumor-to-background ratios and excellent pharmacokinetic behavior. Early human data confirmed its safety and therapeutic potential. The complementary use of [68Ga]Ga\/[161Tb]Tb-DOTA-IBA enables a unified diagnostic-therapeutic platform for the management of bone metastases, providing an innovative, targeted treatment option capable of improving both quality of life and survival in patients with advanced skeletal disease.<\/jats:p>","DOI":"10.1021\/acs.molpharmaceut.5c01869","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T09:52:56Z","timestamp":1784022776000},"page":"4069-4078","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation\nof 161Tb-Labeled DOTA-Ibandronate\nfor Targeted Radionuclide Therapy in Bone Metastases"],"prefix":"10.1021","volume":"23","author":[{"given":"Chunfang","family":"Zhang","sequence":"first","affiliation":[{"name":"The Affiliated Hospital of Southwest Medical University , , , ,","place":["Luzhou, Sichuan, PR China, 646000"]},{"name":"Argeted Radiopharmaceuticals Creation Key Laboratory of Sichuan Province , , ,","place":["Luzhou, Sichuan, PR China, 646000"]},{"name":"Southwest Medical University , , , ,","place":["Luzhou, Sichuan, PR China, 646000"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingwei","family":"Wang","sequence":"additional","affiliation":[{"name":"The Affiliated Hospital of Southwest Medical University , , , ,","place":["Luzhou, Sichuan, PR China, 646000"]},{"name":"Argeted Radiopharmaceuticals Creation Key Laboratory of Sichuan Province , , ,","place":["Luzhou, Sichuan, PR China, 646000"]},{"name":"Southwest Medical University , , , ,","place":["Luzhou, Sichuan, PR China, 646000"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Deng","sequence":"additional","affiliation":[{"name":"The Affiliated Hospital of Southwest Medical University , , , ,","place":["Luzhou, Sichuan, PR China, 646000"]},{"name":"Argeted Radiopharmaceuticals Creation Key Laboratory of Sichuan Province , , ,","place":["Luzhou, Sichuan, PR China, 646000"]},{"name":"Southwest Medical University , , , ,","place":["Luzhou, Sichuan, PR China, 646000"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Die","family":"You","sequence":"additional","affiliation":[{"name":"The Affiliated Hospital of Southwest Medical University , , , ,","place":["Luzhou, Sichuan, PR China, 646000"]},{"name":"Argeted Radiopharmaceuticals Creation Key Laboratory of Sichuan Province , , ,","place":["Luzhou, Sichuan, PR China, 646000"]},{"name":"Southwest Medical University , , , ,","place":["Luzhou, Sichuan, PR China, 646000"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya","family":"Liu","sequence":"additional","affiliation":[{"name":"The Affiliated Hospital of Southwest Medical University , , , ,","place":["Luzhou, Sichuan, PR China, 646000"]},{"name":"Argeted Radiopharmaceuticals Creation Key Laboratory of Sichuan Province , , ,","place":["Luzhou, Sichuan, PR China, 646000"]},{"name":"Southwest Medical University , , , ,","place":["Luzhou, Sichuan, PR China, 646000"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Lei","sequence":"additional","affiliation":[{"name":"The Affiliated Hospital of Southwest Medical University , , , ,","place":["Luzhou, Sichuan, PR China, 646000"]},{"name":"Argeted Radiopharmaceuticals Creation Key Laboratory of Sichuan Province , , ,","place":["Luzhou, Sichuan, PR China, 646000"]},{"name":"Southwest Medical University , , , ,","place":["Luzhou, Sichuan, PR China, 646000"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhao","sequence":"additional","affiliation":[{"name":"The Affiliated Hospital of Southwest Medical University , , , ,","place":["Luzhou, Sichuan, PR China, 646000"]},{"name":"Argeted Radiopharmaceuticals Creation Key Laboratory of Sichuan Province , , ,","place":["Luzhou, Sichuan, PR China, 646000"]},{"name":"Southwest Medical University , , , ,","place":["Luzhou, Sichuan, PR China, 646000"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Yang","sequence":"additional","affiliation":[{"name":"The Affiliated Hospital of Southwest Medical University , , , ,","place":["Luzhou, Sichuan, PR China, 646000"]},{"name":"Argeted Radiopharmaceuticals Creation Key Laboratory of Sichuan Province , , ,","place":["Luzhou, Sichuan, PR China, 646000"]},{"name":"Southwest Medical University , , , ,","place":["Luzhou, Sichuan, PR China, 646000"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0284-5958","authenticated-orcid":true,"given":"Li","family":"Wang","sequence":"additional","affiliation":[{"name":"The Affiliated Hospital of Southwest Medical University , , , ,","place":["Luzhou, Sichuan, PR China, 646000"]},{"name":"Southwest Medical University , , , ,","place":["Luzhou, Sichuan, PR China, 646000"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[{"name":"The Affiliated Hospital of Southwest Medical University , , , ,","place":["Luzhou, Sichuan, PR China, 646000"]},{"name":"Argeted Radiopharmaceuticals Creation Key Laboratory of Sichuan Province , , ,","place":["Luzhou, Sichuan, PR China, 646000"]},{"name":"Southwest Medical University , , , ,","place":["Luzhou, Sichuan, PR China, 646000"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4088-7649","authenticated-orcid":true,"given":"Yue","family":"Chen","sequence":"additional","affiliation":[{"name":"The Affiliated Hospital of Southwest Medical University , , , ,","place":["Luzhou, Sichuan, PR China, 646000"]},{"name":"Argeted Radiopharmaceuticals Creation Key Laboratory of Sichuan Province , , ,","place":["Luzhou, Sichuan, PR China, 646000"]},{"name":"Southwest Medical University , , , ,","place":["Luzhou, Sichuan, PR China, 646000"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,7,14]]},"reference":[{"issue":"3","key":"2026080309074436900_cit1","doi-asserted-by":"publisher","first-page":"388","DOI":"10.3390\/cells11030388","article-title":"Breast Cancer Bone Metastasis: A Narrative Review of\nEmerging Targeted Drug Delivery Systems","volume":"11","author":"Shao","year":"2022","journal-title":"Cells"},{"issue":"12","key":"2026080309074436900_cit2","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1038\/s43018-024-00854-6","article-title":"How\nthe Bone Microenvironment\nShapes the Pre-Metastatic Niche and Metastasis","volume":"5","author":"Jackett","year":"2024","journal-title":"Nat. Cancer"},{"issue":"14","key":"2026080309074436900_cit3","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1002\/jlcr.4128","article-title":"Towards Optimal Automated 68Ga-Radiolabeling Conditions of the DOTA-Bisphosphonate BPAMD\nWithout Pre-Purification of the Generator Eluate","volume":"67","author":"Souche","year":"2024","journal-title":"J. Labelled Compd. Radiopharm."},{"issue":"10","key":"2026080309074436900_cit4","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.2967\/jnumed.115.155762","article-title":"Clinical Efficacy and\nSafety Comparison of 177Lu-EDTMP with 153Sm-EDTMP\non an Equidose Basis in Patients with Painful Skeletal Metastases","volume":"56","author":"Thapa","year":"2015","journal-title":"J. Nucl. Med."},{"issue":"0","key":"2026080309074436900_cit5","doi-asserted-by":"publisher","first-page":"S171","DOI":"10.1007\/s00259-004-1540-y","article-title":"153Sm-EDTMP\nfor Bone Pain Palliation in Skeletal Metastases","volume":"31","author":"Maini","year":"2004","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"7","key":"2026080309074436900_cit6","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.1039\/D4DT03159H","article-title":"Preparation and Preclinical\nEvaluation of 68Ga-Labeled Alendronate Analogs for Diagnosis\nof Bone Metastases","volume":"54","author":"Lin","year":"2025","journal-title":"Dalton Trans."},{"issue":"6","key":"2026080309074436900_cit7","doi-asserted-by":"publisher","first-page":"4793","DOI":"10.1021\/acs.jmedchem.3c02372","article-title":"Theranostic Agent Targeting\nBone Metastasis: A Novel [68Ga]Ga\/[177Lu]Lu-DOTA-HBED-Bisphosphonate","volume":"67","author":"Jin","year":"2024","journal-title":"J. Med. Chem."},{"issue":"2","key":"2026080309074436900_cit8","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1097\/RLU.0000000000005573","article-title":"Efficacy and Safety\nof 177Lu-DOTA-IBA in Tumor Bone Metastasis Treatment: A\nProspective Clinical Trial","volume":"50","author":"Xu","year":"2025","journal-title":"Clin. Nucl. Med."},{"issue":"6","key":"2026080309074436900_cit9","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1097\/RLU.0000000000004634","article-title":"Safety and Efficacy\nof 68Ga- or 177Lu-Labeled DOTA-IBA as a Novel\nTheranostic Radiopharmaceutical for Bone Metastases: A Phase 0\/I Study","volume":"48","author":"Qiu","year":"2023","journal-title":"Clin. Nucl. Med."},{"key":"2026080309074436900_cit10","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.addr.2015.12.003","article-title":"Radioimmunotherapy\nof Cancer with\nHigh Linear Energy Transfer (LET) Radiation Delivered by Radionuclides\nEmitting \u03b1-Particles or Auger Electrons","volume":"109","author":"Aghevlian","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"2","key":"2026080309074436900_cit11","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S1470-2045(23)00638-1","article-title":"Actinium-225-PSMA Radioligand\nTherapy of Metastatic Castration-Resistant Prostate Cancer (WARMTH\nAct): A Multicentre, Retrospective Study","volume":"25","author":"Sathekge","year":"2024","journal-title":"Lancet\nOncol."},{"issue":"7","key":"2026080309074436900_cit12","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1097\/RLU.0000000000004688","article-title":"A New Radiopharmaceutical 225Ac-DOTA-IBA\nin the Treatment of a Case of Bone Metastases","volume":"48","author":"Xu","year":"2023","journal-title":"Clin. Nucl. Med."},{"issue":"8","key":"2026080309074436900_cit13","doi-asserted-by":"publisher","first-page":"2906","DOI":"10.1007\/s00259-025-07168-4","article-title":"Evaluating\nXerostomia\nas a Side Effect of [255Ac]Ac-PSMA Therapy in Prostate\nCancer: A Systematic Review and Meta-Analysis","volume":"52","author":"Al-Ibraheem","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"2026080309074436900_cit14","doi-asserted-by":"publisher","first-page":"109411","DOI":"10.1016\/j.apradiso.2020.109411","article-title":"Activity Standardisation\nof 161Tb","volume":"166","author":"Nedjadi","year":"2020","journal-title":"Appl. Radiat. Isot."},{"issue":"5","key":"2026080309074436900_cit15","doi-asserted-by":"publisher","first-page":"759","DOI":"10.2967\/jnumed.115.170423","article-title":"Dose Deposits from 90Y, 177Lu, 111In, and 161Tb in Micrometastases of\nVarious Sizes: Implications for Radiopharmaceutical\nTherapy","volume":"57","author":"Hindie\u0301","year":"2016","journal-title":"J. Nucl. Med."},{"issue":"4","key":"2026080309074436900_cit16","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s00259-021-05564-0","article-title":"Combination of Terbium-161\nwith Somatostatin Receptor Antagonists-a Potential Paradigm Shift\nfor the Treatment of Neuroendocrine Neoplasms","volume":"49","author":"Borgna","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"9","key":"2026080309074436900_cit17","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1007\/s00259-019-04345-0","article-title":"Terbium-161\nfor PSMA-Targeted\nRadionuclide Therapy of Prostate Cancer","volume":"46","author":"Mu\u0308ller","year":"2019","journal-title":"Eur.\nJ. Nucl. Med. Mol. Imaging"},{"issue":"3","key":"2026080309074436900_cit18","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1007\/s00259-013-2563-z","article-title":"Direct\nin Vitro and\nin Vivo Comparison of 161Tb and 177Lu Using\na Tumour-Targeting Folate Conjugate","volume":"41","author":"Mu\u0308ller","year":"2014","journal-title":"Eur. J.\nNucl. Med. Mol. Imaging"},{"key":"2026080309074436900_cit19","doi-asserted-by":"publisher","first-page":"rs.3.rs-3415703\/v1","DOI":"10.21203\/rs.3.rs-3415703\/v1","article-title":"The Radiolabeling of\n[161Tb]-PSMA-617\nby a Novel Radiolabeling Method and Preclinical Evaluation by In Vitro\/In\nVivo Methods","author":"Uygur","year":"2023","journal-title":"Res. Sq"},{"issue":"10","key":"2026080309074436900_cit20","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.2967\/jnumed.123.265524","article-title":"Albumin-Binding and\nConventional PSMA Ligands in Combination with 161Tb: Biodistribution,\nDosimetry, and Preclinical Therapy","volume":"64","author":"Tschan","year":"2023","journal-title":"J. Nucl.\nMed."},{"issue":"10","key":"2026080309074436900_cit21","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.2967\/jnumed.120.258376","article-title":"First-in-Humans Application\nof 161Tb: A Feasibility Study Using 161Tb-DOTATOC","volume":"62","author":"Baum","year":"2021","journal-title":"J. Nucl. Med."},{"issue":"8","key":"2026080309074436900_cit22","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/S1470-2045(25)00332-8","article-title":"First-in-Human\nResults\nof Terbium-161 [161Tb]Tb-PSMA-I&T Dual Beta\u2013Auger\nRadioligand Therapy in Patients with Metastatic Castration-Resistant\nProstate Cancer (VIOLET): A Single-Centre, Single-Arm, Phase 1\/2 Study","volume":"26","author":"Buteau","year":"2025","journal-title":"Lancet Oncol."},{"issue":"5","key":"2026080309074436900_cit23","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1007\/s00259-024-07009-w","article-title":"First-in-Human Administration\nof [161Tb]Tb-SibuDAB and Comparative Dosimetry with Standard\n[177Lu]Lu-PSMA-I&T as Part of the PROGNOSTICS Phase\nIa Study","volume":"52","author":"Chirindel","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"5","key":"2026080309074436900_cit24","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.7150\/thno.92273","article-title":"[161Tb]Tb-PSMA-617\nRadioligand Therapy in Patients with mCRPC: Preliminary Dosimetry\nResults and Intra-Individual Head-to-Head Comparison to [177Lu]Lu-PSMA-617","volume":"14","author":"Schaefer-Schuler","year":"2024","journal-title":"Theranostics"},{"issue":"8","key":"2026080309074436900_cit25","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.2967\/jnumed.124.267650","article-title":"Clinical Trial Protocol\nfor VIOLET: A Single-Center, Phase I\/II Trial Evaluation of Radioligand\nTreatment in Patients with Metastatic Castration-Resistant Prostate\nCancer with [161Tb]Tb-PSMA-I&T","volume":"65","author":"Buteau","year":"2024","journal-title":"J. Nucl. Med."},{"issue":"7","key":"2026080309074436900_cit26","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.2967\/jnumed.122.265268","article-title":"161Tb-DOTATOC\nProduction Using a Fully Automated Disposable Cassette System: A First\nStep Toward the Introduction of 161Tb into the Clinic","volume":"64","author":"Favaretto","year":"2023","journal-title":"J. Nucl. Med."},{"key":"2026080309074436900_cit27","doi-asserted-by":"publisher","first-page":"1027792","DOI":"10.3389\/fonc.2022.1027792","article-title":"Preparation,\nBiological\nCharacterization and Preliminary Human Imaging Studies of 68Ga-DOTA-IBA","volume":"12","author":"Wang","year":"2022","journal-title":"Front. Oncol."},{"issue":"3","key":"2026080309074436900_cit28","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1021\/acs.molpharmaceut.2c00978","article-title":"Lutetium177-Labeled\nDOTA-Ibandronate: A Novel Radiopharmaceutical for Targeted Treatment\nof Bone Metastases","volume":"20","author":"Wang","year":"2023","journal-title":"Mol. Pharmaceutics"},{"issue":"6","key":"2026080309074436900_cit29","first-page":"895","article-title":"Therapy\nof Metastatic Bone Pain","volume":"42","author":"Serafini","year":"2001","journal-title":"J. Nucl. Med."},{"issue":"1","key":"2026080309074436900_cit30","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s11916-018-0659-7","article-title":"Utility of Radionuclide Bone Scintigraphy\nin Complex Regional Pain Syndrome","volume":"22","author":"Howard","year":"2018","journal-title":"Curr. Pain\nHeadache Rep."}],"container-title":["Molecular Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.molpharmaceut.5c01869","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article-pdf\/23\/8\/4069\/65901661\/acs.molpharmaceut.5c01869.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article-pdf\/23\/8\/4069\/65901661\/acs.molpharmaceut.5c01869.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T13:20:01Z","timestamp":1785763201000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article\/23\/8\/4069\/5207831\/Evaluation-of-161Tb-Labeled-DOTA-Ibandronate-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,14]]},"references-count":30,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,7,14]]},"published-print":{"date-parts":[[2026,8,3]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.molpharmaceut.5c01869","relation":{},"ISSN":["1543-8384","1543-8392"],"issn-type":[{"value":"1543-8384","type":"print"},{"value":"1543-8392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,14]]}}}